Tubocurarine (Tubocurarine Chloride)

08/01/1992 - "Tubocurarine pretreatment (3 mg) resulted in a significant decrease in fasciculations, but myalgia, which occurred in five patients, remained the same. "
01/01/1992 - "Pretreatment combining d-tubocurarine (d-TC, 0.075 mg/kg, sc) and ATS (16 mg/kg, sc) prevented the myonecrosis and fasciculation without protecting AChE against inhibition by these nerve agents. "
03/01/1985 - "Tubocurarine virtually abolished visible fasciculation and, in the dose used, reduced the intensity and duration of the neuromuscular block. "
05/08/1967 - "[Effect of small doses of d-tubocurarine on the prevention of muscle fasciculations and pains after scoline injection]."
10/01/1972 - "A clinical study using D-tubocurarine to prevent post fasciculation muscle pain."

01/10/2000 - "There were two sets of control experiments: in both, animals underwent the same surgical procedures but then either remained at rest for the entire study, or the tibial nerve was stimulated, as in the contraction group, following muscle paralysis with tubocurarine. "
01/01/1986 - "Neither the time of appearance, initial specialization, nor characteristic distribution of these primary fiber types within the limb was altered during the early embryonic period by chronic neuromuscular paralysis induced by D-tubocurarine. "
07/01/1985 - "d-Tubocurarine (d-TC) is a drug commonly used to produce muscle paralysis. "
05/01/1983 - "Paralysis of the embryo with d-tubocurarine prevented the differentiation of type IEMB but not type IIEMB characteristics. "
06/01/1980 - "Diaphragmatic function estimated by transdiaphragmatic pressure (Pdi) was studied in eight normal subjects during progressive partial paralysis with d-tubocurarine (dTc). "

08/01/1995 - "Concomitant administration of d-tubocurarine to burn-injured patients may result in further exaggeration of the aberrant responses to neuromuscular relaxants."
08/01/1995 - "Burn-induced upregulation of AChRs is accentuated by infusion of subparalytic doses of d-tubocurarine. "
04/01/1993 - "Resistance to D-tubocurarine was not seen in burn groups compared with controls. "
11/01/1986 - "The unbound volume of distribution, clearance, and half-life of D-tubocurarine were not significantly different from controls, but the plasma binding and renal elimination at 24 hours was increased in burn patients. "
05/01/1981 - "Hyposensitivity to the nondepolarizing muscle relaxant d-tubocurarine (dTc) has been reported during the treatment of burn injury. "

01/01/1989 - "Induction of myopathy was unaffected by synaptic blockade (150 mumol/l D-tubocurarine). "
05/01/1960 - "Supersensitivity to neostigmine and resistance to d-tubocurarine in mice with hereditary myopathy."
03/01/1988 - "The objective of the present investigation was to assess the comparative efficacy of prophylactic treatment with d-tubocurarine (d-TC) (0.075 mg/kg), atropine sulfate (16 mg/kg), and atropine methylnitrate (16 mg/kg), employed singly or in combination against the diisopropylphosphorofluoridate (DFP)-induced myopathy in rat. "
01/01/1987 - "Prevention of phospholine-induced myopathy with d-tubocurarine, atropine sulfate, diazepam, and creatine phosphate."
01/01/1992 - "Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX."

07/01/1976 - "Pretreatment with a small dose of d-tubocurarine is effective in preventing or decreasing fasciculations, plasma potassium and CPK changes and myoglobinuria described after the intravenous administration of succinylcholine. "